File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Outcomes of growth hormone replacement therapy in survivors of childhood acute lymphoblastic leukemia

TitleOutcomes of growth hormone replacement therapy in survivors of childhood acute lymphoblastic leukemia
Authors
Issue Date2002
Citation
Journal of Clinical Oncology, 2002, v. 20, n. 13, p. 2959-2964 How to Cite?
AbstractPurpose: Little is known about the long-term efficacy or adverse effects of growth hormone (GH) replacement therapy in survivors of childhood acute lymphoblastic leukemia (ALL) who have GH deficiency. We investigated the adult height of patients who had received GH and estimated their risk of leukemia relapse or development of a second malignancy. Patients and Methods: Of 910 patients treated for ALL at a single institution, 47 had received GH replacement therapy. The linear growth of these 47 patients was retrospectively evaluated. Their risk of leukemia relapse or second malignancy was compared with that of survivors who did not undergo GH therapy. Results: The median height SD score at the start of GH therapy had decreased by 1.0 since the time of diagnosis of ALL. After a median duration of 4.5 years of GH therapy, adult height SD scores improved and approached height SD scores at the time of diagnosis of ALL. The median adult height for male patients was 173.2 cm (range, 157 to 191.9 cm), and for female patients, it was 158.1 cm (range, 141 to 168 cm). None of the patients developed adverse effects requiring discontinuation of GH treatment. At the 7-year and 11-year landmarks in continuous hematologic remission, there was no statistical evidence that GH therapy was associated with leukemia relapse or development of a second malignancy. Conclusion: This study suggests that GH replacement therapy is safe and efficacious for the correction of GH deficiency in survivors of childhood ALL. © 2002 by American Society of Clinical Oncology.
Persistent Identifierhttp://hdl.handle.net/10722/294391
ISSN
2020 Impact Factor: 44.544
2020 SCImago Journal Rankings: 10.482
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLeung, Wing-
dc.contributor.authorRose, Susan R.-
dc.contributor.authorZhou, Yinmei-
dc.contributor.authorHancock, Michael L.-
dc.contributor.authorBurstein, Stephen-
dc.contributor.authorSchriock, Elizabeth A.-
dc.contributor.authorLustig, Robert-
dc.contributor.authorDanish, Robert K.-
dc.contributor.authorEvans, William E.-
dc.contributor.authorHudson, Melissa M.-
dc.contributor.authorPui, Ching Hon-
dc.date.accessioned2020-12-03T08:22:37Z-
dc.date.available2020-12-03T08:22:37Z-
dc.date.issued2002-
dc.identifier.citationJournal of Clinical Oncology, 2002, v. 20, n. 13, p. 2959-2964-
dc.identifier.issn0732-183X-
dc.identifier.urihttp://hdl.handle.net/10722/294391-
dc.description.abstractPurpose: Little is known about the long-term efficacy or adverse effects of growth hormone (GH) replacement therapy in survivors of childhood acute lymphoblastic leukemia (ALL) who have GH deficiency. We investigated the adult height of patients who had received GH and estimated their risk of leukemia relapse or development of a second malignancy. Patients and Methods: Of 910 patients treated for ALL at a single institution, 47 had received GH replacement therapy. The linear growth of these 47 patients was retrospectively evaluated. Their risk of leukemia relapse or second malignancy was compared with that of survivors who did not undergo GH therapy. Results: The median height SD score at the start of GH therapy had decreased by 1.0 since the time of diagnosis of ALL. After a median duration of 4.5 years of GH therapy, adult height SD scores improved and approached height SD scores at the time of diagnosis of ALL. The median adult height for male patients was 173.2 cm (range, 157 to 191.9 cm), and for female patients, it was 158.1 cm (range, 141 to 168 cm). None of the patients developed adverse effects requiring discontinuation of GH treatment. At the 7-year and 11-year landmarks in continuous hematologic remission, there was no statistical evidence that GH therapy was associated with leukemia relapse or development of a second malignancy. Conclusion: This study suggests that GH replacement therapy is safe and efficacious for the correction of GH deficiency in survivors of childhood ALL. © 2002 by American Society of Clinical Oncology.-
dc.languageeng-
dc.relation.ispartofJournal of Clinical Oncology-
dc.titleOutcomes of growth hormone replacement therapy in survivors of childhood acute lymphoblastic leukemia-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1200/JCO.2002.09.142-
dc.identifier.pmid12089225-
dc.identifier.scopuseid_2-s2.0-0036645443-
dc.identifier.volume20-
dc.identifier.issue13-
dc.identifier.spage2959-
dc.identifier.epage2964-
dc.identifier.isiWOS:000176583400008-
dc.identifier.issnl0732-183X-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats